Literature DB >> 32341552

Executable cancer models: successes and challenges.

Matthew A Clarke1, Jasmin Fisher2,3.   

Abstract

Making decisions on how best to treat cancer patients requires the integration of different data sets, including genomic profiles, tumour histopathology, radiological images, proteomic analysis and more. This wealth of biological information calls for novel strategies to integrate such information in a meaningful, predictive and experimentally verifiable way. In this Perspective we explain how executable computational models meet this need. Such models provide a means for comprehensive data integration, can be experimentally validated, are readily interpreted both biologically and clinically, and have the potential to predict effective therapies for different cancer types and subtypes. We explain what executable models are and how they can be used to represent the dynamic biological behaviours inherent in cancer, and demonstrate how such models, when coupled with automated reasoning, facilitate our understanding of the mechanisms by which oncogenic signalling pathways regulate tumours. We explore how executable models have impacted the field of cancer research and argue that extending them to represent a tumour in a specific patient (that is, an avatar) will pave the way for improved personalized treatments and precision medicine. Finally, we highlight some of the ongoing challenges in developing executable models and stress that effective cross-disciplinary efforts are key to forward progress in the field.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32341552     DOI: 10.1038/s41568-020-0258-x

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   69.800


  121 in total

Review 1.  Principles for the buffering of genetic variation.

Authors:  J L Hartman; B Garvik; L Hartwell
Journal:  Science       Date:  2001-02-09       Impact factor: 47.728

2.  Waddington's canalization revisited: developmental stability and evolution.

Authors:  Mark L Siegal; Aviv Bergman
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-24       Impact factor: 11.205

3.  Mechanisms of resistance to intermittent androgen deprivation in patients with prostate cancer identified by a novel computational method.

Authors:  Jason D Morken; Aaron Packer; Rebecca A Everett; John D Nagy; Yang Kuang
Journal:  Cancer Res       Date:  2014-05-22       Impact factor: 12.701

Review 4.  Genomic evolution of cancer models: perils and opportunities.

Authors:  Uri Ben-David; Rameen Beroukhim; Todd R Golub
Journal:  Nat Rev Cancer       Date:  2019-02       Impact factor: 60.716

Review 5.  Tumorigenesis: it takes a village.

Authors:  Doris P Tabassum; Kornelia Polyak
Journal:  Nat Rev Cancer       Date:  2015-07-02       Impact factor: 60.716

Review 6.  Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework.

Authors:  David Cook; Dearg Brown; Robert Alexander; Ruth March; Paul Morgan; Gemma Satterthwaite; Menelas N Pangalos
Journal:  Nat Rev Drug Discov       Date:  2014-05-16       Impact factor: 84.694

7.  Impact of a five-dimensional framework on R&D productivity at AstraZeneca.

Authors:  Paul Morgan; Dean G Brown; Simon Lennard; Mark J Anderton; J Carl Barrett; Ulf Eriksson; Mark Fidock; Bengt Hamrén; Anthony Johnson; Ruth E March; James Matcham; Jerome Mettetal; David J Nicholls; Stefan Platz; Steve Rees; Michael A Snowden; Menelas N Pangalos
Journal:  Nat Rev Drug Discov       Date:  2018-01-19       Impact factor: 84.694

8.  Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state.

Authors:  Gloria V Echeverria; Zhongqi Ge; Sahil Seth; Xiaomei Zhang; Sabrina Jeter-Jones; Xinhui Zhou; Shirong Cai; Yizheng Tu; Aaron McCoy; Michael Peoples; Yuting Sun; Huan Qiu; Qing Chang; Christopher Bristow; Alessandro Carugo; Jiansu Shao; Xiaoyan Ma; Angela Harris; Prabhjot Mundi; Rosanna Lau; Vandhana Ramamoorthy; Yun Wu; Mariano J Alvarez; Andrea Califano; Stacy L Moulder; William F Symmans; Joseph R Marszalek; Timothy P Heffernan; Jeffrey T Chang; Helen Piwnica-Worms
Journal:  Sci Transl Med       Date:  2019-04-17       Impact factor: 17.956

Review 9.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

Review 10.  Cancer: evolution within a lifetime.

Authors:  Marco Gerlinger; Nicholas McGranahan; Sally M Dewhurst; Rebecca A Burrell; Ian Tomlinson; Charles Swanton
Journal:  Annu Rev Genet       Date:  2014-10-01       Impact factor: 16.830

View more
  15 in total

1.  Anticancer Effects of Vitis vinifera L. Mediated Biosynthesized Silver Nanoparticles and Cotreatment with 5 Fluorouracil on HT-29 Cell Line.

Authors:  Giray Salman; Suray Pehlivanoglu; Cigdem Aydin Acar; Sukriye Yesilot
Journal:  Biol Trace Elem Res       Date:  2021-09-21       Impact factor: 3.738

2.  Emerging paradigms in metastasis research.

Authors:  Ashik Ahmed Abdul Pari; Mahak Singhal; Hellmut G Augustin
Journal:  J Exp Med       Date:  2021-01-04       Impact factor: 14.307

3.  Construction of a prognostic immune signature for lower grade glioma that can be recognized by MRI radiomics features to predict survival in LGG patients.

Authors:  Zi-Zhuo Li; Peng-Fei Liu; Ting-Ting An; Hai-Chao Yang; Wei Zhang; Jia-Xu Wang
Journal:  Transl Oncol       Date:  2021-03-21       Impact factor: 4.243

Review 4.  Artificial intelligence in cancer research: learning at different levels of data granularity.

Authors:  Davide Cirillo; Iker Núñez-Carpintero; Alfonso Valencia
Journal:  Mol Oncol       Date:  2021-02-20       Impact factor: 6.603

Review 5.  Systems approaches to investigate the role of NF-κB signaling in aging.

Authors:  Masatoshi Haga; Mariko Okada
Journal:  Biochem J       Date:  2022-01-28       Impact factor: 3.857

6.  Executable network of SARS-CoV-2-host interaction predicts drug combination treatments.

Authors:  Rowan Howell; Matthew A Clarke; Ann-Kathrin Reuschl; Tianyi Chen; Sean Abbott-Imboden; Mervyn Singer; David M Lowe; Clare L Bennett; Benjamin Chain; Clare Jolly; Jasmin Fisher
Journal:  NPJ Digit Med       Date:  2022-02-14

7.  The significance of ErbB2/3 in the conversion of induced pluripotent stem cells into cancer stem cells.

Authors:  Ghmkin Hassan; Maram H Zahra; Akimasa Seno; Masaharu Seno
Journal:  Sci Rep       Date:  2022-02-17       Impact factor: 4.379

8.  Unsupervised logic-based mechanism inference for network-driven biological processes.

Authors:  Martina Prugger; Lukas Einkemmer; Samantha P Beik; Perry T Wasdin; Leonard A Harris; Carlos F Lopez
Journal:  PLoS Comput Biol       Date:  2021-06-02       Impact factor: 4.475

9.  Cell Line-Specific Network Models of ER+ Breast Cancer Identify Potential PI3Kα Inhibitor Resistance Mechanisms and Drug Combinations.

Authors:  Jorge Gómez Tejeda Zañudo; Pingping Mao; Joan Montero; Réka Albert; Nikhil Wagle; Clara Alcon; Kailey Kowalski; Gabriela N Johnson; Guotai Xu; Jose Baselga; Maurizio Scaltriti; Anthony Letai
Journal:  Cancer Res       Date:  2021-07-13       Impact factor: 13.312

Review 10.  Global mapping of cancers: The Cancer Genome Atlas and beyond.

Authors:  Carlo Ganini; Ivano Amelio; Riccardo Bertolo; Pierluigi Bove; Oreste Claudio Buonomo; Eleonora Candi; Chiara Cipriani; Nicola Di Daniele; Hartmut Juhl; Alessandro Mauriello; Carla Marani; John Marshall; Sonia Melino; Paolo Marchetti; Manuela Montanaro; Maria Emanuela Natale; Flavia Novelli; Giampiero Palmieri; Mauro Piacentini; Erino Angelo Rendina; Mario Roselli; Giuseppe Sica; Manfredi Tesauro; Valentina Rovella; Giuseppe Tisone; Yufang Shi; Ying Wang; Gerry Melino
Journal:  Mol Oncol       Date:  2021-07-20       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.